Patent ID: 9017673
Filing Date: 2015-04-28
Classification: A61K,A61P,C07C,C07K,Y02A,Y02P

Abstract:
1. A method for the treatment of systemic lupus erythematosus, comprising administering to a patient in need thereof a pharmaceutically acceptable amount of a hybrid peptide containing at least one aza-β 3 aminoacyl residue, selected from the group consisting of: a residue corresponding to formula (A) when the residue is situated at the N-terminal position, wherein R represents H or a protective group of the amine function of the amino acids, and R a residue corresponding to formula (B) when the residue is situated at the C-terminal position, wherein R a residue corresponding to formula (C) when the residue is situated in the chain of the hybrid peptides, wherein R wherein said hybrid peptide comprises amino acids 88-99 of histone H4 (SEQ ID NO: 1), and at least one of said amino acids is replaced by the aza-β